Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Advocates for Arthritis Fly-In Event Benefits Rheumatology Patients

Kelly Tyrrell  |  September 9, 2018

“These were used 30 years ago, and we are talking about 21st century United States, not an underdeveloped country with no access to medication. They have high toxicity and limited benefits for patients with RA,” she says. “At some point, they were all we had, but today methotrexate is a first-line medication used for rheumatoid arthritis.”

Dr. Shakoory was diagnosed with ankylosing spondylitis during her rheumatology fellowship and attends the fly-in because her experiences have given her first-hand knowledge of the challenges and barriers to providing and receiving care.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This year’s agenda also includes asking for dedicated, line-item research funding for RA from the Department of Defense. “It is the second leading cause of medical discharge from the military after battlefield trauma,” says Dr. Harvey.

Participants will also push for improved patient access to dual-energy X-ray absorptiometry (DXA), a bone density test. Medicare reimbursement for DXA has dropped 70% since 2007. This no longer covers the provider cost to administer the test and forces patients to seek scans at hospitals.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Further, attendees will discuss with legislators the unintended consequences of a billing change designed to reduce administrative burden. It calls for consolidating all evaluation and management services into a single billing code.

“Doctors who tend to see highly complex patients will see a decrease in their overall reimbursement, and doctors who see lower-level patients will see a bump in reimbursement,” says Dr. Harvey. “It will not recognize the contributions rheumatologists make in treating complex patients.”

Patient Input & Impact
At the event, longtime attendee Michael Taffe says personal stories matter, and everyone has a different role to play. Mr. Taffe is a rheumatology patient with a passion for helping others.

“I have learned that patients have a different impact on the members [of Congress] than the doctors do,” he says. “Once we understand the agenda of the doctors, … it’s my job to put a real face on what the doctors are talking about and asking for.”

For Nancy Ellis, MBA/MHA, an ARHP member and practice administrator at Piedmont Arthritis Clinic, Greenville, S.C., attending the fly-in in the past has helped her foster relationships with her representatives. “You’ve got a name when something is going down, instead of just sending something to an amorphous email box,” she says.

Attending for the first time can be nerve-wracking, but Mr. Taffe reminds people to be themselves. This is what Sydney Lau hopes to do this year, when she attends for the second time. The high school senior from California says she was really nervous last year, but is setting aside college applications to once again share her personal experience in living with JIA at the national level.

Page: 1 2 3 | Single Page
Share: 

Filed under:American College of RheumatologyLegislation & AdvocacyProfessional Topics Tagged with:Advocacy 101Advocates for ArthritisDepartment of Defense (DoD)dual-energy X-ray absorptiometry (DXA)step therapy

Related Articles
    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    March 20, 2017

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    What Adult Rheumatologists Need to Know about Juvenile Arthritis

    May 1, 2013

    How to recognize distinctions between pediatric and adult arthritis

    A Possible Diagnostic Tool: RheumMadness 2022 AI: JIA Subtypes Scouting Report

    February 14, 2022

    Machine learning is a tool that may help pediatric rheumatologists distinguish between different subtypes of juvenile idiopathic arthritis (JIA) and predict treatment response.

    Pursue Remission

    November 1, 2007

    Disease remission should be the goal for all rheumatologists treating childhood arthritis

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences